FR2809623B1 - Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives) - Google Patents

Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)

Info

Publication number
FR2809623B1
FR2809623B1 FR0013992A FR0013992A FR2809623B1 FR 2809623 B1 FR2809623 B1 FR 2809623B1 FR 0013992 A FR0013992 A FR 0013992A FR 0013992 A FR0013992 A FR 0013992A FR 2809623 B1 FR2809623 B1 FR 2809623B1
Authority
FR
France
Prior art keywords
sildenafil
parkinson
derivatives
treatment
neurodegenerative diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0013992A
Other languages
English (en)
Other versions
FR2809623A1 (fr
Inventor
Sanjuan Benito Arranz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0007161A external-priority patent/FR2809622A1/fr
Application filed by Individual filed Critical Individual
Priority to FR0013992A priority Critical patent/FR2809623B1/fr
Publication of FR2809623A1 publication Critical patent/FR2809623A1/fr
Application granted granted Critical
Publication of FR2809623B1 publication Critical patent/FR2809623B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0013992A 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives) Expired - Fee Related FR2809623B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR0013992A FR2809623B1 (fr) 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007161A FR2809622A1 (fr) 2000-06-05 2000-06-05 Dans le traitement des maladies neurodegeneratives ( notamment alhzeimer et parkinson) utilisation pour un medicament: du sildenafil (ou de ses derives) ou, de la nicotine et du sildenafil (ou des derives des deux)
FR0013992A FR2809623B1 (fr) 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)

Publications (2)

Publication Number Publication Date
FR2809623A1 FR2809623A1 (fr) 2001-12-07
FR2809623B1 true FR2809623B1 (fr) 2003-09-05

Family

ID=27758814

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0013992A Expired - Fee Related FR2809623B1 (fr) 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)

Country Status (1)

Country Link
FR (1) FR2809623B1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006224623A1 (en) * 2005-03-14 2006-09-21 Nycomed Gmbh Method for preventing cardiovascular diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE262899T1 (de) * 1996-01-02 2004-04-15 Aventis Pharma Inc Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
AU779761C (en) * 1999-10-12 2005-09-22 Lilly Icos Llc Medicament for treatment of neuropathies
IL152925A (en) * 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin

Also Published As

Publication number Publication date
FR2809623A1 (fr) 2001-12-07

Similar Documents

Publication Publication Date Title
EP1651195A4 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
NL300258I2 (nl) Farmaceutische samenstelling voor toepassing in debehandeling van.
WO1997048391A3 (fr) Methodes et compositions a base de r-ibuprofene
DE60100866D1 (de) Cyklosporin, Hyaluronsäure und Polysorbate enthaltenes Augenarzneimittel
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
DE60235719D1 (de) Frauenhygieneartikel zur verabreichung von arzneimittel
DE60126321D1 (de) Gelsystem zur ocularen verabreichung von arzneimitteln
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
CA2431565A1 (fr) Nouvelles compositions pharmaceutiques a base d'anticholinergiques et de ciclesonide
HUP0401867A2 (hu) A valproinsav-amid és a 2-valproénsav-amid származékainak használata a fájdalommal és a fejfájással járó betegségek kezelésére vagy megelőzésére
IL152578A0 (en) Ortho-substituted anthranilic acid amides and their use as medicaments
IS6394A (is) Lyfjablanda sem inniheldur solmítriptan
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
NO323466B1 (no) Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
EP0676200A3 (fr) Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
EP0657167A3 (fr) Application de l'oenothéine B pour obtenir un médicament destiné au traitement des troubles liés à l'hyperandrogénie, les compositions pharmaceutiques le contenant et un procédé de préparation à partir d'Epilobium Parviflorum.
FR2809623B1 (fr) Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
HUP0200145A2 (hu) Tianeptin alkalmazása neurodegeneratív betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
FR2810886B1 (fr) Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
PL362566A1 (en) Substituted cyclohexane derivates and the use thereof in medicaments for treating cardiovascular diseases
IL153439A0 (en) Medicines for the prevention and treatment of neurodegenerative diseases
AU2001262741A1 (en) Medicines for the prevention and treatment of neurodegenerative diseases
FR2792319B1 (fr) Procede de preparation de monosulfate de 4 ou 6 disaccharides, leur utilisation en cosmetique et en tant que medicament notamment pour le traitement des maladies du collagene

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060630

D3 Decision to revoke the decision of lapse
CA Change of address
ST Notification of lapse

Effective date: 20140630